Contract Research Organization Services Market / CRO Services Market by Type (Early Phase, Clinical, Lab, Consulting, Data Management), Therapeutic Area (Cancer, Infectious Disease, Neurology, Dermatology, Immunology, Hematology, Vaccines, CGT) - Global Forecast to 2029
Report Code: PH 4672 Jan, 2024, by marketsandmarkets.com
The contract research organization (CRO) services market is projected to reach USD 129.8 billion by 2029 from an estimated USD 82.0 billion in 2024, at a CAGR of 9.6% during the forecast period.
Clinical research efforts have been progressively outsourced to CROs during the past few years. Factors including cost effectiveness, access to technologically advanced infrastructure and regulatory know-how provided by Contract research organisations help market players predict a continuous increase in outsourcing. Moreover, a rising therapeutic pipeline and a changing scene of drug research help to explain market expansion. For businesses in the Contract Research Organisation (CRO) Services industry, the more emphasis on research and development creates opportunities.
Attractive Opportunities in the Contract Research Organization (CRO) Services market
To know about the assumptions considered for the study, Request for Free Sample Report
Contract Research Organization (CRO) Services Market Dynamics
MARKET DRIVER: Increasing number of drugs in pipeline
For the past eight to ten years, the potency of the pipeline has been expanding continuously due to the desire for novel therapies for many indications. Drug candidates under clinical development grew in numbers on the pipeline. For instance, within ten years the research and development pipeline doubled from 10,479 pharmaceuticals in 2013 to 21,292 in 2023. As a result, during the past few years, the percentage of outsourcing of drug development activities has also been rising. With an eye towards using the skills of CROs—including necessary infrastructure, therapeutic expertise, and regulatory experience—the sponsors—including academic institutions and biotechnology and pharmaceutical companies—outsource drug development activities. Consequently, the expansion of the CRO services market results from the increase in the R&D pipeline.
OPPORTUNITY: Growing focus on precision/ personalized medicine
As the benefits offered by personalized medicines have been recognized, the research and development initiatives in the area of precision/ personalized medicine have been growing largely. There has been a consistent growth in the number of products approved as personalized medicines by the US FDA. For instance, the US FDA has approved more than 50 drugs as personalized medicines between 2020 and 2022 which was merely 11 drugs in 2019. Additionally, CROs have also started offering special services for precision/ personalized medicines as well. This is attracting pharmaceutical and Biotech compenies to outsource these trials from CROs as well. Some instances of companies offering associated services include Labcorp, IQVIA, among others.
CHALLENGE: Patient recruitment and retention
Patient recruitment is the process of enrolling individuals for various phases of a clinical research. It is rather important for the result of the clinical investigation. Any clinical study's effectiveness depends critically on efficient patient recruitment and retention all through the trial. From the whole medication development process, patient recruiting has always presented a difficulty. This is mostly the result of various factors, including ignorance, complexity in the inclusion/exclusion criteria, and some longer-lasting trials that provide difficulties for retention. Furthermore another element causing difficulties in patient recruitment is a lack of knowledge about the viewpoint of patients. Decentralised clinical trials (DCT), however, are supposed to reduce the influence of this problem. Since they give time and place liberty to the subjects of the clinical studies, decentralised trials help to effectively recruit patients. Therefore, using DCT more often could help to lessen the consequences of this difficulty in the next years.
Contract Research Organization (CRO) Services Market Ecosystem
Leading organisations in the industry have been running for several years with diversified service portfolios, modern technologies, and powerful worldwide sales and marketing systems. Among the well-known companies in the CRO Services market are IQVIA Inc. (US), Thermo Fisher Scientific Inc. (US), Iicon Plc (Ireland), WuXi AppTec (China), Syneos Health (US), Charles River Laboratories (US), Fortrea, Inc. (US), Pharmaron (China), Eurofins Scientific (Luxembourg) and Medpace (US).
The clinical research services accounted for the largest share of the type segment in overall Contract Research Organization (CRO) Services in 2023.
On the basis of type, the CRO Services market is segmented into Clinical Research Services, Early Phase Development Services, Laboratory Services, Consulting Services and Data Management Services. In 2023, the clinical research services segment accounted for the largest share of the CRO Services market owing to a major factor including growing number of clinical trials from phase 1 to 4 and an increase in the outsourcing of clinical research and development activities among others.
The oncology subsegment of the therapeutic area segment dominated the overall CRO Services market in 2023.
Based on Therapeutic areas, the CRO Services market is segmented into Oncology, Infectious Diseases, CVS Disorders, Neurology, Vaccines, Metabolic Disorders/Endocrinology, Immunological Disorders, Psychiatric, Respiratory Disorders, Dermatology, Ophthalmology, Gastrointestinal diseases, Genitourinary and Women's health, Haematology, and other therapy areas. Owing to factors including the steadily rising number of clinical trials against oncology indications, growing research and development funding channeled for oncology drug development initiatives, and an increasing frequency of various types of cancers in the upcoming years, oncology accounted for the biggest market share.
North America was the largest market for the overall CRO Services market in 2023 and also during the forecast period.
Geographically, the CRO Services market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. The CRO Services market was dominated by North America in 2023, and this dominance is anticipated to continue throughout the forecast period between 2024 and 2029. The market for CRO Services is expanding in the region as a result of factors like growing size of the pharmaceutical industry in the region, and large funds dedicated to pharma R&D, among others.
To know about the assumptions considered for the study, download the pdf brochure
Key Market Players
The prominent players in the CRO Services market are IQVIA Inc. (US), Laboratory Corporation of America Holdings (US), Thermo Fisher Scientific Inc. (US), ICON Plc (Ireland), WuXi AppTec (China), Syneos Health (US), Charles River Laboratories (US), Fortrea, Inc. (US), Pharmaron (China), Eurofins Scientific (Luxembourg) and Medpace (US) among others.
Scope of the Contract Research Organization Services Industry
|
Report Metric |
Details |
|
Market Revenue in 2024 |
$82.0 billion |
|
Projected Revenue by 2029 |
$129.8 billion |
|
Revenue Rate |
Poised to Grow at a CAGR of 9.6% |
|
Market Driver |
Increasing number of drugs in pipeline |
|
Market Opportunity |
Growing focus on precision/ personalized medicine |
This report categorizes the Contract Research Organization Services Market to forecast revenue and analyze trends in each of the following submarkets:
By Type
-
Clinical Research Services
-
By Phase
- Phase III
- Phase II
- Phase I
- Phase IV
-
By Study Design (For Phase III & IV)
- Interventional
- Real World Evidence (RWE)
-
By Phase
-
Early phase development Services
- Chemistry, Manufacturing and Controls Services
-
Preclinical Services
- Pharmacokinetics/ Pharmacodynamics Services
- Toxicology Testing Services
- Other Preclinical Services
- Discovery Studies
-
Laboratory Services
-
Analytical Testing Services
- Physical Characterization Services
- Raw Material Testing Services
- Batch Release Testing Services
- Stability Testing Services
- Other Analytical Testing Services
- Bioanalytical Testing Services
-
Analytical Testing Services
- Consulting Services
- Data Management Services
By Therapeutic Area
- Oncology
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Other Cancer
- Infectious Diseases
- CVS Disorders
- Neurology
- Vaccines
- Metabolic Disorders/Endocrinology
- Immunological Disorders
- Psychiatry
- Respiratory Disorders
- Dermatology
- Ophthalmology
- Gastrointestinal Diseases
- Genitourinary & Women’s Health
- Hematology
- Other Therapeutic Areas
By End User
- Pharmaceutical & Biopharmaceutical Companies
- Medical Device Companies
- Academic Institutes
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
-
Asia Pacific (APAC)
- China
- India
- Japan
- Australia
- South Korea
- New Zealand
- Rest of Asia Pacific (RoAPAC)
-
Latin America
- Brazil
- Mexico
- Rest of Latin America
-
Middle East and Africa
- Middle East
- Africa
Recent Developments
- In October 2023, IQVIA Inc. (US) and argenx (US) entered a strategic collaboration to support treatment for patients suffering from rare autoimmune disorders through innovative and comprehensive technology-enabled pharmacovigilance (PV) safety services and solutions.
- In October 2023, LabCorp announced the acquisition of the outreach laboratory business and selected operating assets of Baystate Health, comprising laboratory service centres operated by Baystate Health throughout Massachusetts, US.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global contract research organization (CRO) services Market?
The global contract research organization (CRO) services market boasts a total revenue value of $129.8 Billion by 2029.
What is the estimated growth rate (CAGR) of the global Contract research organization (CRO) services Market?
The global contract research organization (CRO) services market has an estimated compound annual growth rate (CAGR) of 9.6% and a revenue size in the region of $82.0 Billion in 2024. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS (Page No. - 60)
4.1 CRO SERVICES MARKET OVERVIEW
4.2 NORTH AMERICA: CRO SERVICES MARKET SHARE, BY TYPE & COUNTRY (2022)
4.3 CRO SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
4.4 CRO SERVICES MARKET SHARE, BY END USER, 2022
4.5 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW (Page No. - 64)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing drug R&D pipeline
5.2.1.2 Technological advancements in clinical trials
5.2.1.3 High cost of in-house drug development
5.2.2 OPPORTUNITIES
5.2.2.1 Need for novel clinical trial designs for complex cell & gene therapies
5.2.2.2 Emergence of hybrid models with CRO-CDMO partnerships
5.2.3 CHALLENGES
5.2.3.1 Patient recruitment and retention for clinical trials
5.2.3.2 Shortage of skilled professionals for clinical trials
5.3 MARKET TRENDS
5.3.1 INDUSTRY CONSOLIDATION
5.3.2 DECENTRALIZED CLINICAL TRIALS
5.3.3 REAL-WORLD DATA (RWD) AND REAL-WORLD EVIDENCE (RWE)
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.5 PRICING ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 TECHNOLOGY ANALYSIS
5.9 CASE STUDY ANALYSIS
5.9.1 USING LAB DATA INSIGHTS TO IMPROVE POPULATION MANAGEMENT OF CHRONIC KIDNEY DISEASE (CKD)
5.9.2 IQVIA FOCUSES ON LEVERAGING AI AND ML TO IMPROVE SERVICE OFFERINGS
5.10 KEY CONFERENCES & EVENTS IN 2022–2023
5.11 REGULATORY ANALYSIS
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.12 PORTER’S FIVE FORCES ANALYSIS
5.12.1 THREAT FROM NEW ENTRANTS
5.12.2 THREAT FROM SUBSTITUTES
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 BARGAINING POWER OF SUPPLIERS
5.12.5 DEGREE OF COMPETITION
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.13.2 BUYING CRITERIA FOR CRO SERVICES
6 CRO SERVICES MARKET, BY TYPE (Page No. - 89)
6.1 INTRODUCTION
6.2 CLINICAL RESEARCH SERVICES
6.2.1 PHASE III CLINICAL RESEARCH SERVICES
6.2.1.1 High cost of Phase III trials to drive demand for cost-effective CRO services
6.2.2 PHASE II CLINICAL RESEARCH SERVICES
6.2.2.1 Growing significance of Phase II studies to provide growth opportunities for CROs
6.2.3 PHASE I CLINICAL RESEARCH SERVICES
6.2.3.1 Growing R&D pipeline of pharmaceutical companies to support growth
6.2.4 PHASE IV CLINICAL RESEARCH SERVICES
6.2.4.1 Increasing number of CROs providing post-marketing surveillance to boost market
6.3 EARLY-PHASE DEVELOPMENT SERVICES
6.3.1 CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES
6.3.1.1 Growing need to meet regulatory standards for drugs to drive demand for CMC services
6.3.2 PRECLINICAL SERVICES
6.3.2.1 Pharmacokinetics/Pharmacodynamics services
6.3.2.1.1 Importance of understanding interactions between body and administered drugs to drive uptake of PK/PD studies
6.3.2.2 Toxicology testing services
6.3.2.2.1 Need to prevent late-stage failures to boost demand for toxicology testing
6.3.2.3 Other preclinical services
6.3.3 DISCOVERY STUDIES
6.3.3.1 Increasing reliance on CRO services for target identification and validation to promote growth
6.4 LABORATORY SERVICES
6.4.1 ANALYTICAL TESTING SERVICES
6.4.1.1 Physical characterization services
6.4.1.1.1 Growing need to reduce risk of product failure to drive demand for physical characterization services
6.4.1.2 Raw material testing services
6.4.1.2.1 Need to ensure quality and purity of raw materials to support demand for raw material testing services
6.4.1.3 Batch-release testing services
6.4.1.3.1 Comprehensive portfolio of batch-release testing services offered by CROs to propel growth
6.4.1.4 Stability testing services
6.4.1.4.1 Need to ensure long-term quality, safety, and efficacy of pharmaceutical products to boost uptake of stability testing
6.4.1.5 Other analytical testing services
6.4.2 BIOANALYTICAL TESTING SERVICES
6.4.2.1 Importance of accurate PK/PD studies to drive demand for bioanalytical testing services
6.5 CONSULTING SERVICES
6.5.1 GROWING ADOPTION OF CONSULTING SERVICES FOR FASTER AND MORE STREAMLINED REGULATORY APPROVALS TO BOOST MARKET
6.6 DATA MANAGEMENT SERVICES
6.6.1 DATA MANAGEMENT SERVICES TO RECORD HIGHEST CAGR DURING FORECAST PERIOD
7 CRO SERVICES MARKET, BY THERAPEUTIC AREA (Page No. - 156)
7.1 INTRODUCTION
7.2 ONCOLOGY
7.2.1 BREAST CANCER
7.2.1.1 High prevalence of breast cancer to drive market growth
7.2.2 LUNG CANCER
7.2.2.1 Increasing drug approvals to boost research on lung cancer
7.2.3 COLORECTAL CANCER
7.2.3.1 Increasing incidence of colorectal cancer to drive drug research activities worldwide
7.2.4 PROSTATE CANCER
7.2.4.1 Increasing research initiatives on prostate cancer to drive growth
7.2.5 OTHER CANCERS
7.3 INFECTIOUS DISEASES
7.3.1 INCREASING EPIDEMIC OUTBREAKS TO DRIVE DRUG DISCOVERY ACTIVITIES
7.4 CARDIOVASCULAR SYSTEM DISORDERS
7.4.1 HIGH MORTALITY RATES TO COMPEL PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS
7.5 NEUROLOGY
7.5.1 INCREASING INVESTMENTS IN R&D FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET
7.6 VACCINES
7.6.1 NORMALIZATION OF VACCINES MARKET GROWTH TO PRE-COVID TIMES TO RESTRAIN MARKET GROWTH
7.7 METABOLIC DISORDERS/ENDOCRINOLOGY
7.7.1 INCREASING GLOBAL DIABETES POPULATION TO BOOST MARKET
7.8 IMMUNOLOGICAL DISORDERS
7.8.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH
7.9 PSYCHIATRY
7.9.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL GROWTH
7.10 RESPIRATORY DISORDERS
7.10.1 GROWING BURDEN OF RESPIRATORY DISORDERS TO SUPPORT GROWTH
7.11 DERMATOLOGY
7.11.1 GROWING DRUG DEVELOPMENT FOR VARIOUS SKIN DISORDERS TO PROPEL MARKET
7.12 OPHTHALMOLOGY
7.12.1 GROWING OPHTHALMOLOGY-RELATED CLINICAL TRIALS TO DRIVE SEGMENT
7.13 GASTROINTESTINAL DISEASES
7.13.1 GROWING R&D PIPELINE FOR GASTROINTESTINAL DISEASES TO AID GROWTH
7.14 GENITOURINARY & WOMEN’S HEALTH
7.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL MARKET
7.15 HEMATOLOGY
7.15.1 DEVELOPMENT OF DRUGS FOR HEMATOLOGICAL DISORDERS TO DRIVE GROWTH
7.16 OTHER THERAPEUTIC AREAS
7.17 CUSTOMIZATION
7.17.1 CELL & GENE THERAPY
7.17.1.1 Favorable funding scenario for R&D to support growth
7.17.2 RARE DISEASES
7.17.2.1 Growth in drug R&D pipeline for rare diseases to drive market
7.17.3 BIOSIMILARS
7.17.3.1 Patent expiration of biologics to boost market
7.17.3.2 Monoclonal antibodies
7.17.3.3 Insulin
7.17.3.4 CSF
7.17.3.5 Erythropoietin
7.17.3.6 Other biosimilars
8 CRO SERVICES MARKET, BY END USER (Page No. - 235)
8.1 INTRODUCTION
8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
8.2.1 INCREASING R&D EXPENDITURE AND ROBUST PIPELINES TO DRIVE MARKET GROWTH
8.3 MEDICAL DEVICE COMPANIES
8.3.1 INCREASING R&D FOR DEVELOPMENT OF ADVANCED MEDICAL DEVICES TO SUPPORT GROWTH
8.4 ACADEMIC INSTITUTES
8.4.1 INCREASING COLLABORATIONS BETWEEN CROS AND ACADEMIC INSTITUTES TO BOOST MARKET
9 CRO SERVICES MARKET, BY REGION (Page No. - 248)
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.1.1 US to dominate CRO services market in North America
9.2.2 CANADA
9.2.2.1 Favorable regulations to support market growth
9.2.3 NORTH AMERICA: RECESSION IMPACT
9.3 EUROPE
9.3.1 GERMANY
9.3.1.1 Growing outsourcing and government support to propel market
9.3.2 UK
9.3.2.1 Investments by pharmaceutical sponsors for drug discovery services to boost market
9.3.3 FRANCE
9.3.3.1 Favorable drug research environment to drive market growth
9.3.4 ITALY
9.3.4.1 Low drug approval time and growing research funding to fuel growth
9.3.5 SPAIN
9.3.5.1 Rising R&D expenditure to boost market
9.3.6 REST OF EUROPE
9.3.7 EUROPE: RECESSION IMPACT
9.4 ASIA PACIFIC
9.4.1 CHINA
9.4.1.1 China to dominate APAC CRO services market
9.4.2 JAPAN
9.4.2.1 Strong focus on research to drive market growth
9.4.3 INDIA
9.4.3.1 Growing pharmaceutical industry to create favorable opportunities for market players
9.4.4 AUSTRALIA
9.4.4.1 Large number of research institutes to make Australia a favorable location for drug discovery
9.4.5 SOUTH KOREA
9.4.5.1 Government initiatives and growing R&D activities for drug development to drive growth
9.4.6 REST OF ASIA PACIFIC (ROAPAC)
9.4.7 ASIA PACIFIC: RECESSION IMPACT
9.5 LATIN AMERICA
9.5.1 BRAZIL
9.5.1.1 Gradual growth in research to contribute to growth
9.5.2 REST OF LATIN AMERICA
9.5.3 LATIN AMERICA: RECESSION IMPACT
9.6 MIDDLE EAST & AFRICA
9.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH
9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
10 COMPETITIVE LANDSCAPE (Page No. - 344)
10.1 INTRODUCTION
10.2 STRATEGIES ADOPTED BY KEY PLAYERS
10.3 REVENUE SHARE ANALYSIS
10.4 MARKET SHARE ANALYSIS
10.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
10.6.1 INDUSTRY FOOTPRINT OF COMPANIES (25 COMPANIES)
10.6.2 SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES)
10.6.3 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
10.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES
10.7.1 PROGRESSIVE COMPANIES
10.7.2 STARTING BLOCKS
10.7.3 RESPONSIVE COMPANIES
10.7.4 DYNAMIC COMPANIES
10.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
10.9 COMPETITIVE SCENARIOS AND TRENDS
10.9.1 SERVICE LAUNCHES
10.9.2 DEALS
10.9.3 OTHER DEVELOPMENTS
11 COMPANY PROFILES (Page No. - 360)
11.1 KEY COMPANIES
11.1.1 IQVIA
11.1.1.1 Business overview
11.1.1.2 Services offered
11.1.1.3 Recent developments
11.1.1.4 MnM view
11.1.1.4.1 Right to win
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses and competitive threats
11.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS (LABCORP)
11.1.2.1 Business overview
11.1.2.2 Services offered
11.1.2.3 Recent developments
11.1.2.4 MnM view
11.1.2.4.1 Right to win
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses and competitive threats
11.1.3 PPD INC. (A PART OF THERMO FISHER SCIENTIFIC, INC.)
11.1.3.1 Business overview
11.1.3.2 Services offered
11.1.3.3 Recent developments
11.1.3.4 MnM view
11.1.3.4.1 Right to win
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses and competitive threats
11.1.4 SYNEOS HEALTH INC.
11.1.4.1 Business overview
11.1.4.2 Services offered
11.1.4.3 Recent developments
11.1.4.4 MnM view
11.1.4.4.1 Right to win
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses and competitive threats
11.1.5 WUXI APPTEC CO., LTD.
11.1.5.1 Business overview
11.1.5.2 Services offered
11.1.5.3 Recent developments
11.1.5.4 MnM view
11.1.5.4.1 Right to win
11.1.5.4.2 Strategic choices
11.1.5.4.3 Weaknesses and competitive threats
11.1.6 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
11.1.6.1 Business overview
11.1.6.2 Services offered
11.1.6.3 Recent developments
11.1.6.4 MnM view
11.1.6.4.1 Right to win
11.1.6.4.2 Strategic choices
11.1.6.4.3 Weaknesses and competitive threats
11.1.7 PAREXEL INTERNATIONAL CORPORATION
11.1.7.1 Business overview
11.1.7.2 Services offered
11.1.7.3 Recent developments
11.1.8 PHARMARON BEIJING CO., LTD.
11.1.8.1 Business overview
11.1.8.2 Services offered
11.1.8.3 Recent developments
11.1.9 ICON PLC
11.1.9.1 Business overview
11.1.9.2 Services offered
11.1.9.3 Recent developments
11.1.10 MEDPACE HOLDINGS, INC.
11.1.10.1 Business overview
11.1.10.2 Services offered
11.1.11 SGS SA
11.1.11.1 Business overview
11.1.11.2 Services offered
11.1.11.3 Recent developments
11.1.12 FRONTAGE HOLDINGS CORPORATION
11.1.12.1 Business overview
11.1.12.2 Services offered
11.1.12.3 Recent developments
11.1.13 PSI CRO AG
11.1.13.1 Business overview
11.1.13.2 Services offered
11.1.13.3 Recent developments
11.1.14 BIOAGILE THERAPEUTICS PVT. LTD.
11.1.14.1 Business overview
11.1.14.2 Services offered
11.1.15 FIRMA CLINICAL RESEARCH, LLC
11.1.15.1 Business overview
11.1.15.2 Services offered
11.1.16 ACCULAB LIFE SCIENCES
11.1.16.1 Business overview
11.1.16.2 Services offered
11.1.17 NOVOTECH HEALTH HOLDINGS
11.1.17.1 Business overview
11.1.17.2 Services offered
11.1.17.3 Recent developments
11.1.18 KCR (FORMERLY KIECANA CLINICAL RESEARCH)
11.1.18.1 Business overview
11.1.18.2 Services offered
11.1.18.3 Recent developments
11.1.19 LINICAL CO., LTD.
11.1.19.1 Business overview
11.1.19.2 Services offered
11.1.19.3 Recent developments
11.1.20 ADVANCED CLINICAL
11.1.20.1 Business overview
11.1.20.2 Services offered
11.1.20.3 Recent developments
11.2 OTHER PLAYERS
11.2.1 AZELIX LLC
11.2.2 CLINICAL TRIAL SERVICE BV
11.2.3 PEPGRA HEALTHCARE PVT. LTD.
11.2.4 WORLDWIDE CLINICAL TRIALS HOLDINGS INC.
11.2.5 CTI CLINICAL TRIAL AND CONSULTING SERVICES, INC.
12 APPENDIX (Page No. - 446)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
LIST OF TABLES (529 TABLES)
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
TABLE 4 CRO SERVICES MARKET: IMPACT ANALYSIS
TABLE 5 LIST OF ACQUISITIONS
TABLE 6 OVERALL MARKET ECOSYSTEM FOR CRO SERVICES
TABLE 7 CRO SERVICES MARKET: DETAILED LIST OF CONFERENCES & EVENTS
TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 CRO SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 13 CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 14 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES AS OF DECEMBER 2022, BY LOCATION
TABLE 15 EXAMPLES OF CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS
TABLE 16 CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 17 CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 18 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 19 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 20 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 21 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 22 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE III STUDIES
TABLE 23 PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 24 NORTH AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 EUROPE: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 26 ASIA PACIFIC: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 27 LATIN AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 28 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES
TABLE 29 PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 30 NORTH AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 31 EUROPE: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 32 ASIA PACIFIC: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 LATIN AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 34 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE I STUDIES
TABLE 35 PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 36 NORTH AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 37 EUROPE: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 38 ASIA PACIFIC: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 39 LATIN AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 40 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES
TABLE 41 PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 42 NORTH AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 EUROPE: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 ASIA PACIFIC: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 45 LATIN AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 EXAMPLES OF EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY MARKET PLAYERS
TABLE 47 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 48 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 49 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 50 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 53 CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 54 NORTH AMERICA: CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 EUROPE: CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 56 ASIA PACIFIC: CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 57 LATIN AMERICA: CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 59 PRECLINICAL SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 60 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 61 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 PHARMACOKINETICS/PHARMACOKINETICS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 65 NORTH AMERICA: PHARMACOKINETICS/PHARMACOKINETICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 66 EUROPE: PHARMACOKINETICS/PHARMACOKINETICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 67 ASIA PACIFIC: PHARMACOKINETICS/PHARMACOKINETICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 68 LATIN AMERICA: PHARMACOKINETICS/PHARMACOKINETICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 69 TOXICOLOGY TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 70 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 71 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 72 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 73 LATIN AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 74 OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 75 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 76 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 77 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 LATIN AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 79 DISCOVERY STUDIES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 80 NORTH AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 81 EUROPE: DISCOVERY STUDIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 82 ASIA PACIFIC: DISCOVERY STUDIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 83 LATIN AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS
TABLE 85 LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 86 LABORATORY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 87 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 88 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 89 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 LATIN AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 91 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 92 ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 93 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 94 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 95 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 96 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 97 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 98 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 99 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 100 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 101 LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 102 RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 103 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 104 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 105 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 106 LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 107 BATCH-RELEASE TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 108 NORTH AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 109 EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 110 ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 111 LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 112 STABILITY TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 113 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 114 EUROPE: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 115 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 116 LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 117 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 118 NORTH AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 119 EUROPE: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 120 ASIA PACIFIC: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 121 LATIN AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 122 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 123 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 124 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 125 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 126 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 127 EXAMPLES OF CONSULTING SERVICES OFFERED BY PROMINENT PLAYERS
TABLE 128 CONSULTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 129 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 130 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 131 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 132 LATIN AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 133 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS
TABLE 134 DATA MANAGEMENT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 135 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 136 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 137 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 138 LATIN AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 139 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 140 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2022)
TABLE 141 NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040
TABLE 142 CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 143 CRO SERVICES MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 144 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 145 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 146 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 147 LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 148 CRO SERVICES MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION)
TABLE 149 NORTH AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 150 EUROPE: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 151 ASIA PACIFIC: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 152 LATIN AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 153 CRO SERVICES MARKET FOR LUNG CANCER, BY REGION, 2021–2028 (USD MILLION)
TABLE 154 NORTH AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 155 EUROPE: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 156 ASIA PACIFIC: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 157 LATIN AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 158 CRO SERVICES MARKET FOR COLORECTAL CANCER, BY REGION, 2021–2028 (USD MILLION)
TABLE 159 NORTH AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 160 EUROPE: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 161 ASIA PACIFIC: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 162 LATIN AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 163 CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION)
TABLE 164 NORTH AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 165 EUROPE: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 166 ASIA PACIFIC: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 167 LATIN AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 168 CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 169 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 170 EUROPE: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 171 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 172 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 173 CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 174 NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 175 EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 176 ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 177 LATIN AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 178 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (AS OF DECEMBER 2022)
TABLE 179 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 180 NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 181 EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 182 ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 183 LATIN AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 184 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2022)
TABLE 185 CRO SERVICES MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 186 NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 187 EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 188 ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 189 LATIN AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 190 CRO SERVICES MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)
TABLE 191 NORTH AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 192 EUROPE: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 193 ASIA PACIFIC: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 194 LATIN AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 195 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 196 NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 197 EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 198 ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 199 LATIN AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 200 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2022)
TABLE 201 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 202 NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 203 EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 204 ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 205 LATIN AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 206 CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2021–2028 (USD MILLION)
TABLE 207 NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 208 EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 209 ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 210 LATIN AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 211 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2022)
TABLE 212 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 213 NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 214 EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 215 ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 216 LATIN AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 217 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2022)
TABLE 218 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 219 NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 220 EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 221 ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 222 LATIN AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 223 CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 224 NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 225 EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 226 ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 227 LATIN AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 228 CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 229 NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 230 EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 231 ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 232 LATIN AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 233 CRO SERVICES MARKET FOR GENITOURINARY AND WOMEN’S HEALTH, BY REGION, 2021–2028 (USD MILLION)
TABLE 234 NORTH AMERICA: CRO SERVICES MARKET FOR GENITOURINARY AND WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 235 EUROPE: CRO SERVICES MARKET FOR GENITOURINARY AND WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 236 ASIA PACIFIC: CRO SERVICES MARKET FOR GENITOURINARY AND WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 237 LATIN AMERICA: CRO SERVICES MARKET FOR GENITOURINARY AND WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 238 CRO SERVICES MARKET FOR HEMATOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 239 NORTH AMERICA: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 240 EUROPE: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 241 ASIA PACIFIC: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 242 LATIN AMERICA: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 243 CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION)
TABLE 244 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 245 EUROPE: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 246 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 247 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 248 CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 249 NORTH AMERICA: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 250 EUROPE: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 251 ASIA PACIFIC: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 252 LATIN AMERICA: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 253 CRO SERVICES MARKET FOR RARE DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 254 NORTH AMERICA: CRO SERVICES MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 255 EUROPE: CRO SERVICES MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 256 ASIA PACIFIC: CRO SERVICES MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 257 LATIN AMERICA: CRO SERVICES MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 258 CRO SERVICES MARKET FOR BIOSIMILARS, BY REGION, 2021–2028 (USD MILLION)
TABLE 259 NORTH AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 260 EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 261 ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 262 LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 263 CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 264 CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 265 NORTH AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 266 EUROPE: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 267 ASIA PACIFIC: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 268 LATIN AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 269 CRO SERVICES MARKET FOR INSULIN, BY REGION, 2021–2028 (USD MILLION)
TABLE 270 NORTH AMERICA: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 271 EUROPE: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 272 ASIA PACIFIC: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 273 LATIN AMERICA: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 274 CRO SERVICES MARKET FOR CSF, BY REGION, 2021–2028 (USD MILLION)
TABLE 275 NORTH AMERICA: CRO SERVICES MARKET FOR CSF, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 276 EUROPE: CRO SERVICES MARKET FOR CSF, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 277 ASIA PACIFIC: CRO SERVICES MARKET FOR CSF, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 278 LATIN AMERICA: CRO SERVICES MARKET FOR CSF, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 279 CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY REGION, 2021–2028 (USD MILLION)
TABLE 280 NORTH AMERICA: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 281 EUROPE: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 282 ASIA PACIFIC: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 283 LATIN AMERICA: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 284 CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY REGION, 2021–2028 (USD MILLION)
TABLE 285 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 286 EUROPE: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 287 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 288 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 289 CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 290 CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 291 NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 292 EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 293 ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 294 LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 295 CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 296 NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 297 EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 298 ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 299 LATIN AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 300 CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
TABLE 301 NORTH AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 302 EUROPE: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 303 ASIA PACIFIC: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 304 LATIN AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 305 CRO SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 306 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 307 NORTH AMERICA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 308 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 309 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 310 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 311 NORTH AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 312 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 313 NORTH AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 314 NORTH AMERICA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 315 NORTH AMERICA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 316 US: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 317 US: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 318 US: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 319 US: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 320 US: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 321 US: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 322 US: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 323 US: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 324 US: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 325 CANADA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 326 CANADA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 327 CANADA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 328 CANADA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 329 CANADA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 330 CANADA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 331 CANADA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 332 CANADA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 333 CANADA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 334 EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 335 EUROPE: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 336 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 337 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 338 EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 339 EUROPE: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 340 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 341 EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 342 EUROPE: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 343 EUROPE: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 344 GERMANY: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 345 GERMANY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 346 GERMANY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 347 GERMANY: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 348 GERMANY: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 349 GERMANY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 350 GERMANY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 351 GERMANY: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 352 GERMANY: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 353 UK: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 354 UK: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 355 UK: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 356 UK: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 357 UK: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 358 UK: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 359 UK: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 360 UK: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 361 UK: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 362 FRANCE: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 363 FRANCE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 364 FRANCE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 365 FRANCE: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 366 FRANCE: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 367 FRANCE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 368 FRANCE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 369 FRANCE: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 370 FRANCE: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 371 NUMBER OF CLINICAL TRIALS IN ITALY, BY COMPANY (JANUARY 2022)
TABLE 372 ITALY: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 373 ITALY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 374 ITALY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 375 ITALY: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 376 ITALY: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 377 ITALY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 378 ITALY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 379 ITALY: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 380 ITALY: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 381 SPAIN: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 382 SPAIN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 383 SPAIN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 384 SPAIN: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 385 SPAIN: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 386 SPAIN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 387 SPAIN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 388 SPAIN: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 389 SPAIN: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 390 REST OF EUROPE: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 391 REST OF EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 392 REST OF EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 393 REST OF EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 394 REST OF EUROPE: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 395 REST OF EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 396 REST OF EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 397 REST OF EUROPE: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 398 REST OF EUROPE: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 399 ASIA PACIFIC: CRO SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 400 ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 401 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 402 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 403 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 404 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 405 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 406 ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 407 ASIA PACIFIC: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 408 ASIA PACIFIC: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 409 CHINA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 410 CHINA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 411 CHINA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 412 CHINA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 413 CHINA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 414 CHINA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 415 CHINA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 416 CHINA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 417 CHINA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 418 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2020 VS. 2022
TABLE 419 JAPAN: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 420 JAPAN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 421 JAPAN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 422 JAPAN: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 423 JAPAN: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 424 JAPAN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 425 JAPAN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 426 JAPAN: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 427 JAPAN: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 428 INDIA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 429 INDIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 430 INDIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 431 INDIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 432 INDIA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 433 INDIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 434 INDIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 435 INDIA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 436 INDIA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 437 AUSTRALIA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 438 AUSTRALIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 439 AUSTRALIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 440 AUSTRALIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 441 AUSTRALIA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 442 AUSTRALIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 443 AUSTRALIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 444 AUSTRALIA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 445 AUSTRALIA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 446 SOUTH KOREA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 447 SOUTH KOREA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 448 SOUTH KOREA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 449 SOUTH KOREA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 450 SOUTH KOREA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 451 SOUTH KOREA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 452 SOUTH KOREA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 453 SOUTH KOREA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 454 SOUTH KOREA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 455 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 456 REST OF ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 457 REST OF ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 458 REST OF ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 459 REST OF ASIA PACIFIC: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 460 REST OF ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 461 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 462 REST OF ASIA PACIFIC: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 463 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 464 LATIN AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 465 LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 466 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 467 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 468 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 469 LATIN AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 470 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 471 LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 472 LATIN AMERICA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 473 LATIN AMERICA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 474 BRAZIL: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 475 BRAZIL: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 476 BRAZIL: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 477 BRAZIL: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 478 BRAZIL: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 479 BRAZIL: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 480 BRAZIL: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 481 BRAZIL: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 482 BRAZIL: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 483 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 484 REST OF LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 485 REST OF LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 486 REST OF LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 487 REST OF LATIN AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 488 REST OF LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 489 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 490 REST OF LATIN AMERICA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 491 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 492 MIDDLE EAST & AFRICA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 493 MIDDLE EAST & AFRICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 494 MIDDLE EAST & AFRICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 495 MIDDLE EAST & AFRICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 496 MIDDLE EAST & AFRICA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 497 MIDDLE EAST & AFRICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 498 MIDDLE EAST & AFRICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 499 MIDDLE EAST & AFRICA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 500 MIDDLE EAST & AFRICA: CRO SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 501 CRO SERVICES MARKET: DEGREE OF COMPETITION
TABLE 502 INDUSTRY FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET
TABLE 503 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET
TABLE 504 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET
TABLE 505 CRO SERVICES MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
TABLE 506 CRO SERVICES MARKET: COMPETITIVE BENCHMARKING OF START-UP/SMES
TABLE 507 CRO SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2020–DECEMBER 2022
TABLE 508 CRO SERVICES MARKET: DEALS, JANUARY 2020–DECEMBER 2022
TABLE 509 CRO SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2020–DECEMBER 2022
TABLE 510 IQVIA: BUSINESS OVERVIEW
TABLE 511 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
TABLE 512 PPD INC.: BUSINESS OVERVIEW
TABLE 513 SYNEOS HEALTH INC.: BUSINESS OVERVIEW
TABLE 514 WUXI APPTEC CO., LTD.: BUSINESS OVERVIEW
TABLE 515 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
TABLE 516 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW
TABLE 517 PHARMARON BEIJING CO., LTD.: BUSINESS OVERVIEW
TABLE 518 ICON PLC: BUSINESS OVERVIEW
TABLE 519 MEDPACE HOLDINGS, INC.: BUSINESS OVERVIEW
TABLE 520 SGS SA: BUSINESS OVERVIEW
TABLE 521 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW
TABLE 522 PSI CRO AG: BUSINESS OVERVIEW
TABLE 523 BIOAGILE THERAPEUTICS PVT. LTD.: BUSINESS OVERVIEW
TABLE 524 FIRMA CLINICAL RESEARCH, LLC: BUSINESS OVERVIEW
TABLE 525 ACCULAB LIFE SCIENCES: BUSINESS OVERVIEW
TABLE 526 NOVOTECH HEALTH HOLDINGS: BUSINESS OVERVIEW
TABLE 527 KCR: BUSINESS OVERVIEW
TABLE 528 LINICAL CO., LTD.: BUSINESS OVERVIEW
TABLE 529 ADVANCED CLINICAL: BUSINESS OVERVIEW
LIST OF FIGURES (56 FIGURES)
FIGURE 1 CRO SERVICES MARKET SEGMENTATION
FIGURE 2 RESEARCH DESIGN
FIGURE 3 CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2022
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
FIGURE 6 ILLUSTRATIVE EXAMPLE OF IQVIA: REVENUE SHARE ANALYSIS, 2022
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 9 CRO SERVICES MARKET: CAGR PROJECTIONS, 2023–2028
FIGURE 10 CRO SERVICES MARKET: GROWTH ANALYSIS OF DRIVERS, OPPORTUNITIES, AND CHALLENGES
FIGURE 11 DATA TRIANGULATION METHODOLOGY
FIGURE 12 CRO SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 13 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
FIGURE 14 CRO SERVICES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 15 GEOGRAPHICAL SNAPSHOT: CRO SERVICES MARKET
FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH
FIGURE 17 CLINICAL RESEARCH SERVICES DOMINATED NORTH AMERICAN CRO SERVICES MARKET IN 2022
FIGURE 18 CLINICAL RESEARCH SERVICES TO CONTINUE TO DOMINATE MARKET BY 2028
FIGURE 19 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN CRO SERVICES MARKET FROM 2023 TO 2028
FIGURE 21 CRO SERVICES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
FIGURE 22 ACTIVE PHARMACEUTICAL PIPELINE, 2012–2022
FIGURE 23 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028
FIGURE 24 AVERAGE COST OF DEVELOPING PHARMACEUTICAL COMPOUNDS FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION)
FIGURE 25 REVENUE SHIFT & NEW POCKETS FOR CRO SERVICE PROVIDERS
FIGURE 26 VALUE CHAIN ANALYSIS OF CRO SERVICES MARKET: CLINICAL RESEARCH PHASE ADDS MAXIMUM VALUE
FIGURE 27 ECOSYSTEM ANALYSIS: CRO SERVICES MARKET
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CRO SERVICES
FIGURE 29 KEY BUYING CRITERIA FOR END USERS
FIGURE 30 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2021 VS. 2022
FIGURE 31 DRUGS IN DEVELOPMENT, BY THERAPEUTIC AREA (2022)
FIGURE 32 NUMBER OF ONCOLOGY CLINICAL TRIALS, 2012–2022 (THOUSAND)
FIGURE 33 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION)
FIGURE 34 ANNUAL DRUG APPROVALS BY CDER (FDA), 2012–2021
FIGURE 35 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2011–2021
FIGURE 36 US FDA DE NOVO MEDICAL DEVICE APPROVALS (2012–2022)
FIGURE 37 NORTH AMERICA: CRO SERVICES MARKET SNAPSHOT
FIGURE 38 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022)
FIGURE 39 UK: PHARMACEUTICAL R&D EXPENDITURE, 2011–2020 (USD MILLION)
FIGURE 40 ASIA PACIFIC: CRO SERVICES MARKET SNAPSHOT
FIGURE 41 CRO SERVICES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022
FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
FIGURE 44 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
FIGURE 45 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
FIGURE 46 IQVIA: COMPANY SNAPSHOT (2021)
FIGURE 47 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021)
FIGURE 48 PPD INC.: COMPANY SNAPSHOT (2021)
FIGURE 49 SYNEOS HEALTH INC.: COMPANY SNAPSHOT (2021)
FIGURE 50 WUXI APPTEC CO., LTD.: COMPANY SNAPSHOT (2021)
FIGURE 51 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2021)
FIGURE 52 PHARMARON BEIJING CO., LTD.: COMPANY SNAPSHOT (2021)
FIGURE 53 ICON PLC: COMPANY SNAPSHOT (2021)
FIGURE 54 MEDPACE HOLDINGS, INC.: COMPANY SNAPSHOT (2021)
FIGURE 55 SGS SA: COMPANY SNAPSHOT (2021)
FIGURE 56 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021)
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global CRO Services market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
The secondary sources referred to for this research study include publications from public sources, such as the Association of Clinical Research Organizations (ACRO), Clinical Research Society (CRS), Clinical Research Association of Canada (CRAC), Association of International Contract Research Organizations (AICRO), Clinical and Contract Research Association (CCRA), ClinicalTrials.gov website, American Association of Pharmaceutical Scientists (AAPS), Eurostat, Food and Drug Administration (FDA), Pharmaceutical Research and Manufacturers of America (PhRMA), Japan CRO Association, Chinese Association for Laboratory Animal Sciences (CALAS), and Indian Society for Clinical Research (ISCR) among others. Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; business and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global CRO Services market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global CRO services market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, from Tier 1 and Tier 2 companies engaged in offering services) across five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 70% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining share. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the CRO services market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Global CRO Services Market Size: Bottom Up Approach
Bottom-up approach was used to estimate and validate the total size of the CRO Services market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research
- The revenues generated from the CRO Services business of leading players have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
To know about the assumptions considered for the study, Request for Free Sample Report
Global CRO Services Market Size: Top Down Approach
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from the supply side majorly.
Market Definition
CROs are companies that offer research services on a contract basis to various pharmaceutical and biotechnology companies, medical device companies, and academic institutes. These services include clinical research services, early-phase development services, laboratory services, consulting services, and data management services. A sponsor (i.e., a company investigating the safety and efficacy of new drugs, therapies, or medical devices) partners with a CRO on a contractual or project-by-project basis. The CRO provides advice and guidance for planning, designing, and executing clinical trials; it offers a comprehensive and diverse range of services for each phase of the clinical trial.
Key Stakeholders
- Pharmaceutical & biopharmaceutical companies
- Medical device manufacturing companies
- Academic & research institutes
- Venture capitalists & investors
- Market research & consulting firms
- Government associations
- Medical institutions & universities
Report Objectives
- To define, describe, and forecast the contract research organization (CRO) services market based on type, therapeutic area, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (drivers, opportunities, and challenges) along with the current trends
- To strategically analyze micromarkets with respect to their individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the revenue of market segments with respect to five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
- To profile the key players and comprehensively analyze their market shares and core competencies
- To track and analyze competitive developments in the CRO services market, such as service launches, agreements, partnerships, collaborations, mergers & acquisitions, and research & development activities
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Portfolio Assessment
- Service Matrix, which gives a detailed comparison of the service portfolios of the top three companies.
Company Information
- Detailed analysis and profiling of additional market players (up to 5).
Geographical Analysis
- A further breakdown of the Rest of Asia Pacific CRO services market into countries
- A further breakdown of the Rest of European CRO services market into countries
- A further breakdown of the Rest of Latin American CRO services market into countries
Generating Response ...
Growth opportunities and latent adjacency in Contract Research Organization Services Market
Which are the driving factors of the contract research organization services market?
Who are the major players operating in the contract research organization services market?
Which region will lead the global contract research organization services market?